Traders Buy Large Volume of Esperion Therapeutics Call Options (NASDAQ:ESPR)

Esperion Therapeutics, Inc. (NASDAQ:ESPRGet Free Report) was the recipient of some unusual options trading on Monday. Stock traders bought 5,316 call options on the company. This represents an increase of 74% compared to the typical daily volume of 3,048 call options.

Esperion Therapeutics Stock Up 3.9 %

ESPR opened at $2.91 on Tuesday. Esperion Therapeutics has a 52 week low of $0.70 and a 52 week high of $3.40. The business has a fifty day simple moving average of $2.30 and a 200-day simple moving average of $2.29. The firm has a market cap of $551.33 million, a P/E ratio of -2.94 and a beta of 1.00.

Esperion Therapeutics (NASDAQ:ESPRGet Free Report) last posted its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.42. The firm had revenue of $137.74 million for the quarter, compared to analyst estimates of $53.11 million. Sell-side analysts expect that Esperion Therapeutics will post -0.05 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. StockNews.com lowered Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 17th. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 target price on shares of Esperion Therapeutics in a research report on Tuesday, May 21st. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 target price on shares of Esperion Therapeutics in a research note on Tuesday, May 7th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $9.33.

Get Our Latest Research Report on ESPR

Institutional Trading of Esperion Therapeutics

Hedge funds have recently made changes to their positions in the business. Bellevue Group AG raised its stake in shares of Esperion Therapeutics by 136.5% in the first quarter. Bellevue Group AG now owns 9,944,064 shares of the biopharmaceutical company’s stock valued at $26,650,000 after acquiring an additional 5,739,800 shares in the last quarter. Vanguard Group Inc. raised its position in Esperion Therapeutics by 71.8% in the 1st quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company’s stock valued at $23,655,000 after purchasing an additional 3,688,796 shares in the last quarter. Armistice Capital LLC purchased a new position in shares of Esperion Therapeutics in the 4th quarter valued at about $9,568,000. GSA Capital Partners LLP grew its position in shares of Esperion Therapeutics by 159.1% during the third quarter. GSA Capital Partners LLP now owns 1,116,655 shares of the biopharmaceutical company’s stock worth $1,094,000 after buying an additional 685,733 shares in the last quarter. Finally, Wasatch Advisors LP increased its stake in shares of Esperion Therapeutics by 2.7% during the first quarter. Wasatch Advisors LP now owns 9,129,647 shares of the biopharmaceutical company’s stock worth $24,467,000 after buying an additional 238,544 shares during the period. Institutional investors and hedge funds own 47.39% of the company’s stock.

About Esperion Therapeutics

(Get Free Report)

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

Featured Articles

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.